Efficacy & Safety of Orally Administered Valsartan/Amlodipine Combo Therapy vs Amlodipine Monotherapy in Black Patients With Stage II Hypertension
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Read our disclaimer for details.
The purpose of this study is to evaluate the blood pressure lowering effects of a valsartan/amlodipine combination treatment and amlodipine monotherapy for the treatment of Black stage II hypertensive patients (MSSBP ≥ 160 mmHg).
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Layout table for eligibility information
Ages Eligible for Study:
18 Years and older (Adult, Older Adult)
Sexes Eligible for Study:
18 years of age or older.
Moderate to severe high blood pressure. This is defined as a systolic pressure (the top number) greater than or equal to 160 mmHg and less than 200 mmHg.
History of allergy or hypersensitivity to ARBs, CCBs, thiazide diuretics
Inability to stop all prior blood pressure medications safely
Systolic BP ≥ 200 mmHg and/or diastolic BP ≥ 120 mmHg
Controlled blood pressure (systolic BP < 140 mmHg) taking more than 3 antihypertensive medications at screening
Systolic BP ≥ 140 mmHg and < 180 mmHg taking more than two antihypertensive medications at screening
Systolic BP ≥ 180 mmHg taking more than one antihypertensive medication at screening
History of autoimmune diseases
History of multiple drug allergies
Pancreatic injury within 1 year of screening
Evidence of kidney impairment or history of dialysis
Any surgical or medical condition which might alter the absorption, distribution, metabolism, or excretion of any drug. This could include currently active gastritis, ulcers, or gastrointestinal/rectal bleeding, or urinary tract obstruction.
Women of child-bearing potential (WOCBP), defined as all women physiologically capable of becoming pregnant, would be excluded UNLESS they are post-menopausal, surgically sterile OR are using acceptable methods of contraception. The use of hormonal contraceptives is not allowed
Pregnant or nursing (lactating) women
History of malignancy of any organ system within the past five years
Any severe, life-threatening disease within the past five years
History of drug or alcohol abuse within the last 2 years.
History of stroke, angioplasty, coronary artery bypass graft surgery, heart attack or unstable angina
Type 1 diabetes
Poorly controlled Type 2 diabetes
History of heart failure
Significant valvular heart disease
Other protocol-defined inclusion/exclusion criteria may apply
Membrane Transport Modulators
Molecular Mechanisms of Pharmacological Action
Calcium-Regulating Hormones and Agents
Physiological Effects of Drugs
Angiotensin II Type 1 Receptor Blockers
Angiotensin Receptor Antagonists